MNPR compared with IVVD: revenue, margins and what each company keeps, and the suppliers and customers both name

MNPRMonopar Therapeutics

Mkt capRevenueRevenue

IVVDInvivyd, Inc.

Mkt capRevenueRevenue

Compare

MNPRMonopar Therapeutics

IVVDInvivyd, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

MNPR

Reportimpliedrealized× implied

Q2 FY26—▲+0.38%—

May 14 '26—▼−0.73%—

Q1 FY26—▼−0.84%—

Q3 FY25—▲+5.36%—

IVVD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±48.9%▲+5.13%×0.10

= impliedMNPR realized, solidIVVD realized, hatchedOne scale, both sides: full bar = 49%× = |realized| ÷ impliedSource: market data

MNPRMonopar Therapeutics

71.11▲+5.79%· post 71.11

Mkt cap$479.4MRevenue—Revenue—

IVVDInvivyd, Inc.

0.56▼−4.10%· post 0.56

ClosedNov 6 '26

Mkt cap$165.9MRevenue$14MQ2 FY26Revenue$53MFY25

Compare

ClosedNov 6 '26

MNPRMonopar Therapeutics

IVVDInvivyd, Inc.

71.11▲+5.79%post 71.11

Price

0.56▼−4.10%post 0.56

$479.4M

Mkt cap

$165.9M

—

Revenue

$14MQ2 FY26

—

Revenue

$53MFY25

MNPR71.11▲+5.79%vsIVVD0.56▼−4.10%ClosedNov 6 '26